Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene

Richard H. Shao, Xuejun Tian, Gullu Gorgun, Alexander G. Urbano, Francine M. Foss

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

DAB389IL-2 (ONTAK) is a fusion protein consisting of the ADP-ribosyltransferase and membrane translocating domains of native diphtheria toxin and the full-length sequence for interleukin-2 (IL-2) gene. In vitro data demonstrates that DAB389IL-2 is cytotoxic to cells expressing the high affinity IL-2 receptor (IL-2R). In Phases I and II clinical trials of patients whose tumor cells express a component of the IL-2R, the response rates were 18% for B-cell non-Hodgkin lymphoma (NHL) and 30% for cutaneous T-cell lymphoma (CTCL). In this study, we examined the effects of arginine butyrate on IL-2R expression and susceptibility of leukemia cells to intoxication by DAB389IL-2. We demonstrate that the p75 subunit of the IL-2R (IL-2Rβ) is upregulated in the presence of low concentrations of arginine butyrate (0.06mM) which had no direct growth inhibitory effect on the cells. To explore mechanisms of this upregulation, we examined the effect of 0.06mM arginine butyrate on relevant transcriptional elements and on histone deacetylase and found activation of cAMP response element (CRE) but not NFAT or NFKB, as well as inhibition of histone deacetylase (HDAC). Our results suggest that the effects of physiologically achievable concentrations of butyrate on IL-2R expression could be exploited to enhance the susceptibility of intermediate and low-affinity IL-2R expressing leukemia cells to DAB389IL-2.

Original languageEnglish (US)
Pages (from-to)1077-1083
Number of pages7
JournalLeukemia Research
Volume26
Issue number12
DOIs
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Interleukin-2 Receptors
Lymphoma
Leukemia
Up-Regulation
Genes
Histone Deacetylases
ADP Ribose Transferases
Diphtheria Toxin
Cutaneous T-Cell Lymphoma
Phase II Clinical Trials
Clinical Trials, Phase I
Butyrates
Response Elements
B-Cell Lymphoma
arginine butyrate
Non-Hodgkin's Lymphoma
Interleukin-2
Membranes
Growth
Neoplasms

Keywords

  • Arginine butyrate
  • Cutaneous T-cell lymphoma (CTCL)
  • DABIL-2
  • Histone deacetylase (HDAC) inhibitor
  • IL-2 receptor (IL-2R)
  • Interleukin-2 (IL-2)
  • ONTAK
  • Signal transduction pathway
  • T-cell lymphoma/leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. / Shao, Richard H.; Tian, Xuejun; Gorgun, Gullu; Urbano, Alexander G.; Foss, Francine M.

In: Leukemia Research, Vol. 26, No. 12, 01.12.2002, p. 1077-1083.

Research output: Contribution to journalArticle

Shao, Richard H. ; Tian, Xuejun ; Gorgun, Gullu ; Urbano, Alexander G. ; Foss, Francine M. / Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. In: Leukemia Research. 2002 ; Vol. 26, No. 12. pp. 1077-1083.
@article{df625e5e95a5444c9cd1ce34808eedb9,
title = "Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene",
abstract = "DAB389IL-2 (ONTAK) is a fusion protein consisting of the ADP-ribosyltransferase and membrane translocating domains of native diphtheria toxin and the full-length sequence for interleukin-2 (IL-2) gene. In vitro data demonstrates that DAB389IL-2 is cytotoxic to cells expressing the high affinity IL-2 receptor (IL-2R). In Phases I and II clinical trials of patients whose tumor cells express a component of the IL-2R, the response rates were 18{\%} for B-cell non-Hodgkin lymphoma (NHL) and 30{\%} for cutaneous T-cell lymphoma (CTCL). In this study, we examined the effects of arginine butyrate on IL-2R expression and susceptibility of leukemia cells to intoxication by DAB389IL-2. We demonstrate that the p75 subunit of the IL-2R (IL-2Rβ) is upregulated in the presence of low concentrations of arginine butyrate (0.06mM) which had no direct growth inhibitory effect on the cells. To explore mechanisms of this upregulation, we examined the effect of 0.06mM arginine butyrate on relevant transcriptional elements and on histone deacetylase and found activation of cAMP response element (CRE) but not NFAT or NFKB, as well as inhibition of histone deacetylase (HDAC). Our results suggest that the effects of physiologically achievable concentrations of butyrate on IL-2R expression could be exploited to enhance the susceptibility of intermediate and low-affinity IL-2R expressing leukemia cells to DAB389IL-2.",
keywords = "Arginine butyrate, Cutaneous T-cell lymphoma (CTCL), DABIL-2, Histone deacetylase (HDAC) inhibitor, IL-2 receptor (IL-2R), Interleukin-2 (IL-2), ONTAK, Signal transduction pathway, T-cell lymphoma/leukemia",
author = "Shao, {Richard H.} and Xuejun Tian and Gullu Gorgun and Urbano, {Alexander G.} and Foss, {Francine M.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1016/S0145-2126(02)00059-0",
language = "English (US)",
volume = "26",
pages = "1077--1083",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene

AU - Shao, Richard H.

AU - Tian, Xuejun

AU - Gorgun, Gullu

AU - Urbano, Alexander G.

AU - Foss, Francine M.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - DAB389IL-2 (ONTAK) is a fusion protein consisting of the ADP-ribosyltransferase and membrane translocating domains of native diphtheria toxin and the full-length sequence for interleukin-2 (IL-2) gene. In vitro data demonstrates that DAB389IL-2 is cytotoxic to cells expressing the high affinity IL-2 receptor (IL-2R). In Phases I and II clinical trials of patients whose tumor cells express a component of the IL-2R, the response rates were 18% for B-cell non-Hodgkin lymphoma (NHL) and 30% for cutaneous T-cell lymphoma (CTCL). In this study, we examined the effects of arginine butyrate on IL-2R expression and susceptibility of leukemia cells to intoxication by DAB389IL-2. We demonstrate that the p75 subunit of the IL-2R (IL-2Rβ) is upregulated in the presence of low concentrations of arginine butyrate (0.06mM) which had no direct growth inhibitory effect on the cells. To explore mechanisms of this upregulation, we examined the effect of 0.06mM arginine butyrate on relevant transcriptional elements and on histone deacetylase and found activation of cAMP response element (CRE) but not NFAT or NFKB, as well as inhibition of histone deacetylase (HDAC). Our results suggest that the effects of physiologically achievable concentrations of butyrate on IL-2R expression could be exploited to enhance the susceptibility of intermediate and low-affinity IL-2R expressing leukemia cells to DAB389IL-2.

AB - DAB389IL-2 (ONTAK) is a fusion protein consisting of the ADP-ribosyltransferase and membrane translocating domains of native diphtheria toxin and the full-length sequence for interleukin-2 (IL-2) gene. In vitro data demonstrates that DAB389IL-2 is cytotoxic to cells expressing the high affinity IL-2 receptor (IL-2R). In Phases I and II clinical trials of patients whose tumor cells express a component of the IL-2R, the response rates were 18% for B-cell non-Hodgkin lymphoma (NHL) and 30% for cutaneous T-cell lymphoma (CTCL). In this study, we examined the effects of arginine butyrate on IL-2R expression and susceptibility of leukemia cells to intoxication by DAB389IL-2. We demonstrate that the p75 subunit of the IL-2R (IL-2Rβ) is upregulated in the presence of low concentrations of arginine butyrate (0.06mM) which had no direct growth inhibitory effect on the cells. To explore mechanisms of this upregulation, we examined the effect of 0.06mM arginine butyrate on relevant transcriptional elements and on histone deacetylase and found activation of cAMP response element (CRE) but not NFAT or NFKB, as well as inhibition of histone deacetylase (HDAC). Our results suggest that the effects of physiologically achievable concentrations of butyrate on IL-2R expression could be exploited to enhance the susceptibility of intermediate and low-affinity IL-2R expressing leukemia cells to DAB389IL-2.

KW - Arginine butyrate

KW - Cutaneous T-cell lymphoma (CTCL)

KW - DABIL-2

KW - Histone deacetylase (HDAC) inhibitor

KW - IL-2 receptor (IL-2R)

KW - Interleukin-2 (IL-2)

KW - ONTAK

KW - Signal transduction pathway

KW - T-cell lymphoma/leukemia

UR - http://www.scopus.com/inward/record.url?scp=0036889625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036889625&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(02)00059-0

DO - 10.1016/S0145-2126(02)00059-0

M3 - Article

C2 - 12443879

AN - SCOPUS:0036889625

VL - 26

SP - 1077

EP - 1083

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 12

ER -